WHO halts hydroxychloroquine trial in COVID-19 following safety concernsThe World Health Organisation has halted clinical tests of hydroxychloroquine against COVID-19, after safety concerns emerged in a Share XWHO halts hydroxychloroquine trial in COVID-19 following safety concernshttps://pharmaphorum.com/news/who-halts-hydroxychloroquine-trial-in-covid-19-following-safety-concerns/
EU regulators warn over safety of Trump’s favourite COVID drugsAs the search for therapies for COVID-19 continues, European regulators have urged caution over the cardiac side-effects of Share XEU regulators warn over safety of Trump’s favourite COVID drugshttps://pharmaphorum.com/news/eu-regulators-warn-over-safety-of-trumps-favourite-covid-drug/
Servier to acquire Danish cancer biotech SymphogenFrance’s Servier has signed a deal to buy the Danish biotech Symphogen, which specialises in antibody-based therapies for Share XServier to acquire Danish cancer biotech Symphogenhttps://pharmaphorum.com/news/servier-to-acquire-danish-biotech-symphogen/
FDA says all ranitidine drugs should be recalled on safety concernsThe FDA has asked drugmakers to pull all prescription and over-the-counter products based on ranitidine off the market Share XFDA says all ranitidine drugs should be recalled on safety concernshttps://pharmaphorum.com/news/fda-says-all-ranitidine-drugs-should-be-recalled-on-safety-concerns/
CHMP backs safety of anticoagulants after real-world studyThe EMA’s human drugs advisory committee has said that no change is needed to the use of direct Share XCHMP backs safety of anticoagulants after real-world studyhttps://pharmaphorum.com/news/chmp-backs-safety-of-anticoagulants-after-real-world-study/
Novartis’ Beovu safety woes could cost billions of dollars, says analystThe launch of Novartis’ Beovu ophthalmology drug could be compromised after a safety warning from doctors over several Share XNovartis’ Beovu safety woes could cost billions of dollars, says analysthttps://pharmaphorum.com/news/novartis-beovu-launch-could-be-hit-by-safety-warning/
Jury trial levies $750m damages on J&J over talc and cancerThe jury in a New Jersey trial has awarded $750 million in punitive damages against Johnson & Johnson Share XJury trial levies $750m damages on J&J over talc and cancerhttps://pharmaphorum.com/news/jury-trial-levies-750m-damages-on-jj-over-talc-and-cancer/
FDA slaps hold on Zolgensma trials as animal data raises safety questionThe FDA has placed a partial clinical hold on Novartis’ recently-approved gene therapy Zolgensma for spinal muscular atrophy Share XFDA slaps hold on Zolgensma trials as animal data raises safety questionhttps://pharmaphorum.com/news/fda-slaps-hold-on-zolgensma-trials-as-animal-data-raises-safety-question/
Major US retailers pull J&J’s talc from shelves over asbestos fearsA trio of major US retailers including Walmart are removing all 22-ounce bottles of Johnson & Johnson’s baby Share XMajor US retailers pull J&J’s talc from shelves over asbestos fearshttps://pharmaphorum.com/news/major-us-retailers-pull-jjs-talc-from-shelves-over-asbestos-fears/
